Literature DB >> 34778969

The mitochondrial regulator PGC1α is induced by cGMP-PKG signaling and mediates the protective effects of phosphodiesterase 5 inhibition in heart failure.

Guangshuo Zhu1, Kazutaka Ueda2,3, Masaki Hashimoto2, Manling Zhang1, Masayuki Sasaki1, Taro Kariya1, Hideyuki Sasaki1, Nina Kaludercic1, Dong-Ik Lee1, Djahida Bedja1, Matthew Gabrielson1, Yuan Yuan1, Nazareno Paolocci1, Robert M Blanton3, Richard H Karas3, Michael E Mendelsohn3,4, Brian O'Rourke1, David A Kass1, Eiki Takimoto1,2.   

Abstract

Phosphodiesterase 5 inhibition (PDE5i) activates cGMP-dependent protein kinase (PKG) and ameliorates heart failure; however, its impact on cardiac mitochondrial regulation has not been fully determined. Here, we investigated the role of the mitochondrial regulator peroxisome proliferator-activated receptor γ co-activator-1α (PGC1α) in the PDE5i-conferred cardioprotection, utilizing PGC1α null mice. In PGC1α+/+ hearts exposed to 7 weeks of pressure overload by transverse aortic constriction, chronic treatment with the PDE5 inhibitor sildenafil improved cardiac function and remodeling, with improved mitochondrial respiration and upregulation of PGC1α mRNA in the myocardium. By contrast, PDE5i-elicited benefits were abrogated in PGC1α-/- hearts. In cultured cardiomyocytes, PKG overexpression induced PGC1α, while inhibition of the transcription factor CREB abrogated the PGC1α induction. Together, these results suggest that the PKG-PGC1α axis plays a pivotal role in the therapeutic efficacy of PDE5i in heart failure.
© 2021 Federation of European Biochemical Societies.

Entities:  

Keywords:  PGC1α; cyclic guanosine monophosphate; heart failure; mitochondria

Mesh:

Substances:

Year:  2021        PMID: 34778969      PMCID: PMC9199229          DOI: 10.1002/1873-3468.14228

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   3.864


  38 in total

Review 1.  PGC-1 coactivators in the cardiovascular system.

Authors:  Ian S Patten; Zolt Arany
Journal:  Trends Endocrinol Metab       Date:  2011-11-01       Impact factor: 12.015

2.  PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.

Authors:  Marco Guazzi; Marco Vicenzi; Ross Arena; Maurizio D Guazzi
Journal:  Circ Heart Fail       Date:  2010-10-29       Impact factor: 8.790

Review 3.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

4.  Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP.

Authors:  J D Chiche; S M Schlutsmeyer; D B Bloch; S M de la Monte; J D Roberts; G Filippov; S P Janssens; A Rosenzweig; K D Bloch
Journal:  J Biol Chem       Date:  1998-12-18       Impact factor: 5.157

5.  Restoration of CREB function is linked to completion and stabilization of adaptive cardiac hypertrophy in response to exercise.

Authors:  Peter A Watson; Jane E B Reusch; Sylvia A McCune; Leslie A Leinwand; Stephen W Luckey; John P Konhilas; David A Brown; Adam J Chicco; Genevieve C Sparagna; Carlin S Long; Russell L Moore
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-03-02       Impact factor: 4.733

Review 6.  What turns CREB on?

Authors:  Mona Johannessen; Marit Pedersen Delghandi; Ugo Moens
Journal:  Cell Signal       Date:  2004-11       Impact factor: 4.315

7.  Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide.

Authors:  Enzo Nisoli; Emilio Clementi; Clara Paolucci; Valeria Cozzi; Cristina Tonello; Clara Sciorati; Renata Bracale; Alessandra Valerio; Maura Francolini; Salvador Moncada; Michele O Carruba
Journal:  Science       Date:  2003-02-07       Impact factor: 47.728

8.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  Paul W Armstrong; Burkert Pieske; Kevin J Anstrom; Justin Ezekowitz; Adrian F Hernandez; Javed Butler; Carolyn S P Lam; Piotr Ponikowski; Adriaan A Voors; Gang Jia; Steven E McNulty; Mahesh J Patel; Lothar Roessig; Joerg Koglin; Christopher M O'Connor
Journal:  N Engl J Med       Date:  2020-03-28       Impact factor: 91.245

9.  Natriuretic peptides enhance the oxidative capacity of human skeletal muscle.

Authors:  Stefan Engeli; Andreas L Birkenfeld; Pierre-Marie Badin; Virginie Bourlier; Katie Louche; Nathalie Viguerie; Claire Thalamas; Emilie Montastier; Dominique Larrouy; Isabelle Harant; Isabelle de Glisezinski; Stefanie Lieske; Julia Reinke; Bibiana Beckmann; Dominique Langin; Jens Jordan; Cedric Moro
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

10.  NecroX-5 protects mitochondrial oxidative phosphorylation capacity and preserves PGC1α expression levels during hypoxia/reoxygenation injury.

Authors:  Vu Thi Thu; Hyoung Kyu Kim; Le Thanh Long; Bayalagmaa Nyamaa; In-Sung Song; To Thanh Thuy; Nguyen Quang Huy; Jubert Marquez; Soon Ha Kim; Nari Kim; Kyung Soo Ko; Byoung Doo Rhee; Jin Han
Journal:  Korean J Physiol Pharmacol       Date:  2016-02-23       Impact factor: 2.016

View more
  3 in total

1.  Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome.

Authors:  Angela N Baybayon-Grandgeorge; Ashley E Pietra; Shelley D Miyamoto; Anastacia M Garcia
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-12

Review 2.  Cyclic GMP and PKG Signaling in Heart Failure.

Authors:  Genri Numata; Eiki Takimoto
Journal:  Front Pharmacol       Date:  2022-04-11       Impact factor: 5.988

3.  Cellular Redox Metabolism Is Modulated by the Distinct Localization of Cyclic Nucleotide Phosphodiesterase 5A Isoforms.

Authors:  Silvia Cardarelli; Adriana Erica Miele; Federica Campolo; Mara Massimi; Patrizia Mancini; Stefano Biagioni; Fabio Naro; Mauro Giorgi; Michele Saliola
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.